Key result
Early, staged PCI of non-culprit lesions in STEMI patients was associated with lower out-of-hospital major cardiovascular events but higher in-hospital major cardiovascular events.
Why the study?
Does early, staged PCI of non-culprit lesions reduce MACE in patients with STEMI and multivessel CAD treated by primary angioplasty?
Cohort (n=110)
Does early, staged PCI of non-culprit lesions reduce MACE in patients with STEMI and multivessel CAD treated by primary angioplasty?
Early staged PCI of non-culprit lesions in STEMI patients with multivessel disease reduces long-term MACE but is associated with increased in-hospital periprocedural myocardial infarction.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in STEMI with multivessel disease; leaves open the net benefit of staged non-culprit PCI for randomized confirmation.
BACKGROUND: Optimal treatment strategy of patients with ST elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD) undergoing primary angioplasty is still unclear. Percutaneous coronary intervention (PCI) of non-culprit vessels simultaneously or soon after primary angioplasty is feasible and safe, but available data failed to consistently show a benefit in long-term clinical outcomes. METHODS: We retrospectively compared in-hospital and long-term outcomes for patients with STEMI and multivessel CAD treated by primary angioplasty with (Group 1, n=64) or without (Group 2, n=46) early, staged PCI of other angiographically significant coronary lesions. In-hospital major adverse cardiovascular events (MACE) were defined as a composite of death, periprocedural myocardial infarction after staged, elective PCI, stroke, stent thrombosis, major bleeding, and vascular complications. MACE at follow-up were defined as a composite of death, stroke, stent thrombosis, any coronary revascularization, and re-hospitalization for acute coronary syndrome. RESULTS: Group 1 patients underwent staged PCI 5.9 +/- 3.5 days after primary angioplasty. The mean length of follow-up was 13 months (392 +/- 236 days). The incidence of in-hospital MACE was 20.3% in Group 1 and 10.8% in Group 2 (P=0.186); the incidence of out of hospital MACE was 9.3% in Group 1 and 23.9% in Group 2 (P=0.037). In Group 1 in-hospital MACE were driven by periprocedural myocardial infarction after the elective procedure, which occurred in 15.6% of patients. CONCLUSIONS: Our data show that multivessel, staged PCI in STEMI patients is associated with a low incidence of adverse events at follow-up but with a higher incidence of in-hospital MACE, mainly driven by periprocedural myocardial infarction during the elective procedure.
No takes yet. Share an insight, caveat, or question.
Rigattieri et al. (2007) conducted a cohort in ST elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD) (n=110). Early, staged PCI of non-culprit lesions vs. Primary angioplasty without early, staged PCI was evaluated on Out of hospital MACE (composite of death, stroke, stent thrombosis, any coronary revascularization, and re-hospitalization for acute coronary syndrome) (p=0.037). Early, staged PCI of non-culprit lesions in STEMI patients was associated with lower out-of-hospital major cardiovascular events but higher in-hospital major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: